The MEK inhibitor cobimetinib has shown some benefits in treating pediatric low-grade gliomas (LGG), although the overall response rate (ORR) remains modest, with a partial response (PR) observed in only 5% of patients. Here, MAP2K7 is linked to low grade glioma.